---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-000150"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:24:08.496744+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products

## Summary
- Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.
- Initial 2-year term auto-renewing; royalty on Net Sales (percentage redacted) due quarterly.
- Marketing through Sonoma's existing EU distribution network; NovaBay retains rights outside territories.
- NovaBay represents it owns the marks, but applications in EU are still pending as previously disclosed.

## SEC filing metadata
- accession: 0001683168-24-000150
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/0001683168-24-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-000150
- JSON: https://secwatch.observer/filing/0001683168-24-000150.json
- Plain text: https://secwatch.observer/filing/0001683168-24-000150.txt

## Key facts
- Material Agreements
  Sonoma Pharmaceuticals, Inc. entered into a license with NovaBay Pharmaceuticals, Inc. (effective 2024-01-05).
  - Action: entry
  - Agreement: license
  - Counterparty: NovaBay Pharmaceuticals, Inc.
  - Effective: 2024-01-05
  source text: Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367083/000168316824000150/0001683168-24-000150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.